May 20, 2014

SSRI and risk of fracture

Q# 11-06: Serotonin reuptake inhibitors and risk of fracture 

This project, that originated with a query by Health Canada, was funded in March 2013 (PI: Sasha Bernatsky) and is already completed.

To respond to this query, our team ensured access to the CaMos (Canadian Multicentre Osteoporosis Study) database.

We presented preliminary results at the CAPT Conference in November 2013.

Moura C, Bernatsky S, Rahme E, Beauchamp M-E, Bessette L, Adachi J, Papaioannou A, Goltzman D, Prior J, Kreiger N, Towheed T, Leslie W, Kaiser, Pickard L, Ioannidis, Fraser L-A, Abrahamowicz M. Psychotropic medication use and 10-year incident fracture risk in men and women ages 50 and older in the population-based Canadian Multicentre Osteoporosis Study (CaMOS). CAPT – ATCP Conference in Toronto, Montreal, QC, November 17-19, 2013.

Since then, our results have been presented and approved by the Health Canada.

We also prepared and published a manuscript in the high-ranking journal Osteoporosis International in January 2014.

Our results lend additional support to the hypothesis that SSRI/SNRI use is associated with an increased risk of fragility fractures. Given the high prevalence of antidepressants use, and the impact of fractures on health, our findings may have a significant clinical impact.

For more information contact: Jessica (Lifang) Wang. Research Coordinator. [email protected]   514.934.1934 ext.44718